We report the selective inactivation of proteolytic antibodies (Abs) to an autoantigen, the neuropeptide vasoactive intestinal peptide (VIP), by a covalently reactive analog (CRA) of VIP containing an electrophilic phosphonate diester at the Lys 20 residue. The VIP-CRA was bound irreversibly by a monoclonal Ab that catalyzes the hydrolysis of VIP. The reaction with the VIP-CRA proceeded more rapidly than with a hapten CRA devoid of the VIP sequence. The covalent binding occurred preferentially at the light chain subunit of the Ab. Covalent VIP-CRA binding was inhibited by VIP devoid of the phosphonate diester group. These results indicate the importance of noncovalent VIP recognition in guiding Ab nucleophilic attack on the phosphonate group. Consistent with the covalent binding data, the VIP-CRA inhibited catalysis by the recombinant light chain of this Ab with potency greater than the hapten-CRA. Catalytic hydrolysis of VIP by a polyclonal VIPase autoantibody preparation that cleaves multiple peptide bonds located between residues 7 and 22 essentially was inhibited completely by the VIP-CRA, suggesting that the electrophilic phosphonate at Lys 20 enjoys sufficient conformational freedom to react covalently with Abs that cleave different peptide bonds in VIP. These results suggest a novel route to antigen-specific covalent targeting of pathogenic Abs.Specific antigen recognition by the variable domains underlies the pathogenic effects of certain Abs 1 produced as a result of autoimmune, allergic, and anti-transplant reactions. For instance, Abs found in myasthenia gravis (reviewed in Ref. 1) and hemophilia (reviewed in Ref.2) bind important epitopes of the acetylcholine receptor and Factor VIII, respectively, that interfere with the biological activity of these proteins by a steric hindrance mechanism. Other Abs utilize their constant region to mediate pathogenic effects, but antigen recognition by Ab variable domains is the stimulus initiating these effects, e.g. Ab recognition of erythrocyte antigens stimulates complement activation by the constant region in autoimmune hemolytic anemia and incompatible blood transfusions. Similarly, allergen recognition by IgE bound to receptors for the constant region on the surface of mast cells stimulates their degranulation. In other diseases, the mechanism of Ab pathogenicity is less clear. For example, Abs to nucleic acids in lupus (reviewed in Ref.3) and to thyroglobulin in Hashimoto's thyroiditis (reviewed in Ref. 4) are unambiguously disease-associated but additional immune abnormalities are also evident in these diseases and the precise functional effects of the Abs remain debatable. Recently, a novel variable domain mechanism underlying Ab pathogenicity has emerged, viz. the catalytic cleavage of antigens. Hydrolytic catalysts such as Abs to polypeptides (5-8) and nucleic acids (9) hold the potential of permanent antigen inactivation. Moreover, catalysts are endowed with turnover capability, i.e. a single Ab molecule can hydrolyze multiple antigen molecules, sugges...